Dainippon Sumitomo Pharma America Announces FDA Acceptance Of Lurasidone New Drug Application For Treatment Of Schizophrenia
Mar 11th, 2010 | By buddy1 | Category: 35, Health & Wellness News, Mental HealthDainippon Sumitomo Pharma America, Inc. (DSPA), a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP), announced that the U.S. Food and Drug Administration (FDA) recently accepted for review the lurasidone New Drug Application (NDA) for the treatment of patients with acute schizophrenia. The NDA was submitted to FDA on December 30, 2009 and will [...] Read more »




